Lenegres Disease Market is By Product Type (Herbs, Spices, Essential Oils, Others (Plant Extracts, Medicinal Plants)), By Application (Food and Bevera....
Market Size in USD
CAGR6.8%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.8% |
Market Concentration | High |
Major Players | GlaxoSmithKline (GSK), F. Hoffmann-La Roche AG, Pfizer Limited, Sanofi SA, Eli Lilly & Company |
The Global Lenegres Disease Market is estimated to be valued at USD 792.3 Mn in 2024 and is expected to reach USD 1,255.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031. Lenegres disease is a rare genetic eye disorder that causes fluid build-up under the retina. The increasing prevalence of genetic eye disorders globally primarily drives the growth of this market.
The global Lenegres disease market is expected to witness steady growth over the forecast period. The market is anticipated to grow due to the rising genetic testing and increasing healthcare expenditure. In addition, the development of novel drug formulations and gene therapies for the treatment of Lenegres disease is expected to provide lucrative opportunities for market players. However, the shortage of treatment options and low diagnosis rates in developing nations are some of the factors expected to hinder the market growth.